SOLV: 10-K Risk Factor Changes

2026 vs 2025  ·  SEC EDGAR  ·  2026-06-01
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

15
New Risks
1
Removed
7
Modified
32
Unchanged
🟢 New in Current Filing

Regulation of Medical Devices and Pharmaceutical Products

The products Solventum develops, manufactures, and commercializes are regulated in most of the markets Solventum serves. Some of these products meet the definition of medical devices, pharmaceuticals or combination products and are regulated, as such, by various governmental…

Read full text

The products Solventum develops, manufactures, and commercializes are regulated in most of the markets Solventum serves. Some of these products meet the definition of medical devices, pharmaceuticals or combination products and are regulated, as such, by various governmental bodies, globally. All products produced by the MedSurg and Dental Solutions segments, with 10 10 10 10 10 10 Table of Contents Table of Contents Table of Contents very few exceptions, meet the definition of a medical device or pharmaceutical product. Accordingly, the development, manufacture, and commercialization of these products must comply with the regulations governing medical devices or pharmaceuticals in the markets we serve. Conversely, none of the products produced by the Health Information Systems segment meet the definition of medical devices or pharmaceuticals. The product portfolio of the segment is dynamic and changes with time, depending on the needs of the customers served. While the Health Information Systems segment does not currently include medical devices or pharmaceutical products, this may change in the future. Determinations of the safety and efficacy of our products are solely within the authority of the United States Food and Drug Administration ("FDA") or other applicable regulatory authorities in jurisdictions outside the United States.

🟢 New in Current Filing United States 🔒
🟢 New in Current Filing European Union 🔒
🟢 New in Current Filing Regulation on Advertising, Marketing, and Promotion 🔒
🟢 New in Current Filing Data Privacy Laws 🔒
🟢 New in Current Filing Global Healthcare Compliance 🔒
🟢 New in Current Filing Quality and Safety 🔒
🟢 New in Current Filing Environmental, Health, and Safety Laws 🔒
🟢 New in Current Filing Information about our Executive Officers 🔒
🟢 New in Current Filing Ethics and Governance 🔒
🟢 New in Current Filing Additional Information 🔒
🟢 New in Current Filing The transfer to Solventum of certain contracts, permits and other assets and rights may have required the consents or approvals of, or provide other rights to, third parties and governmental authorities. If such consents or approvals were not 🔒
🟢 New in Current Filing The deployment and use of artificial intelligence ("AI"), machine learning, or other emerging technologies in Solventum’s products and services, including as part of its research and development efforts, or its failure to adapt its products or services to industry trends and developments related to such technologies in a timely manner, or at all, could adversely affect Solventum’s business, financial condition, results of operations and cash flows. 🔒
🟢 New in Current Filing Solventum may not be able to effectively integrate acquired businesses into its operations or achieve expected cost savings or profitability from its acquisitions. 🔒
🟢 New in Current Filing Solventum’s restructuring program may not be successful or Solventum may not fully realize the expected cost savings and/or operating efficiencies from its restructuring initiatives. 🔒
🔴 No Match in Current Filing Summary of Risk Factors 🔒
🟡 Modified Information Technology and Intellectual Property Risks 🔒
🟡 Modified Solventum’s accounting and other management systems and resources may not be adequately prepared to meet the financial reporting and other requirements to which it is subject to as a standalone publicly traded company following the Spin-Off. 🔒
🟡 Modified Climate change and the impacts of climate change may materially adversely affect Solventum’s business, results of operations, financial condition and cash flows. 🔒
🟡 Modified obtained, Solventum may not be entitled to the full benefit of such contracts, permits and other assets and rights, which could increase its expenses or otherwise harm its business and financial performance. 🔒
🟡 Modified Acquisitions, strategic alliances, divestitures and other strategic events resulting from portfolio management actions and other evolving business strategies, and possible further organizational restructuring, could affect future results. 🔒
🟡 Modified Changes in interest rates could adversely affect Solventum. 🔒
🟡 Modified Public health crises may increase Solventum’s cost of doing business and disrupt Solventum’s operations. 🔒
22 more changes in this filing

Full diff access, historical comparisons, and cross-company signal tracking.

Get full access — from $29/month Already a Pro subscriber? View full diff →